SAN FRANCISCO (MarketWatch) -- Oncolytics Biotech Inc. /zigman2/quotes/204741333/composite ONCY +3.70% /zigman2/quotes/203812837/delayed CA:ONC +3.57% said Wednesday it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency to begin a clinical trial using intravenous administration of reolysin in combination with gemcitabine in patients with advanced cancers including pancreatic, lung and ovarian. Reolysin is Oncolytics' proprietary formulation of the human reovirus. Preclinical studies demonstrated that the combination of gemcitabine and reolysin was synergistic against selected cancer cell lines, the Calgary, Alberta-based company said. Oncolytics shares rose 4.8% to $2.19 in Wednesday morning trade.